PIP: Clinical observation on the use of various oral contraceptive (OC) formulations and the
normal hormonal cycle formed the basis for development of Ortho-Novum 7/7/7, a triphasic …

Cycle control and tolerance were studied in a group of 55 female volunteers, who took
during 42 consecutive days a modern low-dose oral contraceptive: gestodene 75 …

Objective: Comparison of the effect of oral contraceptives on hemostatic variables in venous
thrombosis patients (thrombosis while using oral contraceptives) with the effect in healthy …

Effective cycle control was demonstrated based on two multicenter, 2-year studies of the
triphasic oral contraceptive (OC) agent containing the new progestin norgestimate. The …

The purpose of this study was to compare cycle control, efficacy and side effects of an oral
contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a reference …

Background Four studies published since December, 1995, reported that the incidence of
venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) …

The monophasic low-dose contraceptive containing 30 μg of ethinyl estradiol and 75 μg of
gestodene has been tested in numerous clinical studies to determine contraceptive …

The oral contraceptive is one of the most widely taken medications in the healthy population.
The clinically important side-effects are venous and arterial thrombosis. Accurate estimates …

This clinical investigation of a low-dose, monophasic gestodene-containing oral
contraceptive (75 μg gestodene/30 μg ethinylestradiol), investigated contraceptive efficacy …

This prospective, double-blind, randomized study was conducted to compare the
contraceptive reliability, cycle control, and tolerability of a 23-day versus a 21-day oral …